Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of
/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.
/PRNewswire/ The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and.
Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INterventional Strategies) and VIVA (Vascular InterVentional Advances) Annual Conference have been announced. Leading physicians and researchers will present results from 21 clinical trials, from Monday, October 31, to Wednesday, November 2, at Wynn Las Vegas.